For informational and research purposes only. Not medical advice. Content is aggregated from public sources. Always consult a qualified healthcare provider.
Anti-Aging & Longevity · Comparison

GHK-Cu vs SS-31

A neutral, side-by-side comparison of two anti-aging & longevity peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.

GHK-CuSS-31
CategoryAnti-Aging & LongevityAnti-Aging & Longevity
Also known asCopper Peptide GHK-Cu, Glycyl-L-histidyl-L-lysine copper, Copper Tripeptide-1Elamipretide, MTP-131, Bendavia, Szeto-Schiller peptide 31
EvidenceResearch-stageInvestigational (in trials)
Dosing range1mg–3mg mg, daily to every other day (injectable); twice daily (topical)1mg–10mg mg, daily or every other day
AdministrationSubcutaneous injection, Topical application (cream, serum — most common consumer use), Intradermal injection (skincare clinics)Subcutaneous injection, Intravenous (clinical trials)
Key side effectsInjection site redness (transient), Mild skin irritation with topical (typically resolves with reduced frequency), Rarely reported: metallic taste (with injectable use at higher doses)Injection site reactions, Nausea (rare), Generally well-tolerated in clinical trial populations
Cited sources4 references2 references

Key differences

  • Evidence level differs: GHK-Cu is research-stage, while SS-31 is investigational (in trials).
  • Administration: GHK-Cu — Subcutaneous injection, Topical application (cream, serum — most common consumer use), Intradermal injection (skincare clinics); SS-31 — Subcutaneous injection, Intravenous (clinical trials).
  • Frequency: GHK-Cu is typically daily to every other day (injectable); twice daily (topical); SS-31 is daily or every other day.
  • Research depth: this profile cites 4 sources for GHK-Cu vs 2 for SS-31.

How each works

GHK-Cu

GHK-Cu has been studied for its ability to stimulate collagen, elastin, and glycosaminoglycan synthesis, promote wound healing, and exhibit antioxidant and anti-inflammatory effects. Gene-expression work by Pickart and colleagues found GHK altered expression (>50% up or down) in roughly 32% of assayed human genes — the basis of the widely-cited '~4,000 genes' figure. Its evidence is strongest for in-vitro and topical/cosmetic use; robust human trials of injectable/systemic GHK-Cu are lacking.

SS-31

SS-31 selectively accumulates in mitochondria and binds cardiolipin — a phospholipid critical for the electron transport chain. By stabilizing cardiolipin, SS-31 restores ATP production, reduces reactive oxygen species (ROS), and prevents mitochondrial permeability transition. Animal studies show dramatic reversal of mitochondrial dysfunction in aged tissues.

Read the full GHK-Cu profileRead the full SS-31 profile

This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.